Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Rank in Stocks #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Share Price
$0.74834668
Market Cap
$45.86M
Change (1 day)
-0.15%
Change (1 year)
-6.28%
Country
SE
Trade Mendus AB (publ) (IMMU)

Category

Dividend yield history for Mendus AB (publ) (IMMU)
Mendus AB (publ) (stock symbol: IMMU) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Mendus AB (publ) (IMMU) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US